retatrutide clinical trial results 2024 2025 retatrutide weight loss study Retatrutide, Eli Lilly's next obesity shot, showed far more in patients than other blockbuster obesity drugs. MORE BELOW ⬇️ New Phase 3 retatrutide data

With tirzepatide, patients lose an average of 15-22% of body weight (40-56 pounds for a 250-pound person)

The brains of the mice were removed, frozen, and embedded in Optimal Compound Temperature compound (Sakura Finetek, USA)

GLP-1-related fatigue often presents as: Persistent low energy despite adequate sleep Mental fog or difficulty concentrating Physical weakness or feeling heavy Lack of motivation for usual activities Energy that comes and goes in waves Feeling more tired after eating (or not eating) This type of fatigue tends to feel different from ordinary tiredness and may fluctuate, especially around dose increases, significant dietary changes, or periods of rapid weight loss

A five-day cycle means consistently higher drug levels, which increases side effect risk without proportional benefit